Garden State Investment Advisory Services’s AstraZeneca AZN Stock Holding History

Garden State Investment Advisory Services’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,536	Closed	-$239K	–	280
2024 Q3	$239K	Buy	1,536 +1	+0.1%	+$161	0.08%	195
2024 Q2	$239K	Sell	1,535 -14	-0.9%	-$2.11K	0.08%	190
2024 Q1	$210K	Sell	1,549 -221	-12%	-$29.3K	0.08%	205
2023 Q4	$238K	Buy	1,770 +33	+2%	+$4.29K	0.09%	175
2023 Q3	$235K	Buy	1,737 +30	+2%	+$4.1K	0.11%	160
2023 Q2	$244K	Buy	+1,707	New	+$251K	0.1%	169

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Garden State Investment Advisory Services's AZN Position: Q4 2024 in Review

Garden State Investment Advisory Services sold out of AstraZeneca (AZN) in Q4 2024, closing a stake of 1,536 shares — an estimated $239K sold.

Garden State Investment Advisory Services first reported a position in AZN in Q2 2023 and held it in 6 quarters. The position peaked at $244K in Q2 2023. 1,219 funds tracked by Wall St. Rank hold AZN as of Q4 2024.

Garden State Investment Advisory Services reported no remaining AstraZeneca position as of Q4 2024 after selling out during the quarter.
Garden State Investment Advisory Services sold 1,536 AstraZeneca shares in Q4 2024, an estimated $239K.
Garden State Investment Advisory Services first reported a position in AstraZeneca in Q2 2023 and held it in 6 quarters.
Garden State Investment Advisory Services's AstraZeneca position peaked at $244K in Q2 2023.
1,219 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2024.

Based on Garden State Investment Advisory Services's 13F filing for Q4 2024, filed 13 Feb 2025.